Sanderling Venture Partners VI LP

Filings by Sanderling Venture Partners VI LP span 2 companies, the busiest being Pacira BioSciences, Inc. and CalciMedica, Inc. Over a trading history stretching from 8 February 2011 to 23 January 2024, the count stands at 84 filings.

In open-market terms, that means 12 purchases worth €3.7M on one side and 28 sales worth €35.7M on the other. The net balance comes to €32.0M on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 25 share grants. In 2024 alone, the filings show 7 purchases and no sales.

A typical purchase (the median) is worth €159k. On 7 out of 7 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. Looking at 12 purchases old enough to measure, the stock rose over the following 90 days in 42% of cases; the median change was -5.0%. These figures describe past trades and do not predict future prices.

The newest entry dates from 25 January 2024: an open-market purchase of €98k, in CalciMedica, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.